Literature DB >> 27087288

Ibrutinib-related atrial fibrillation in patients with mantle cell lymphoma.

Hun Ju Lee1, Dai Chihara1, Michael Wang1, Elie Mouhayar2, Peter Kim2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27087288     DOI： 10.3109/10428194.2016.1169408

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  4 in total

Review 1.  Cardiovascular Complications of Cancer Therapy: Best Practices in Diagnosis, Prevention, and Management: Part 2.

Authors:  Hui-Ming Chang; Tochukwu M Okwuosa; Tiziano Scarabelli; Rohit Moudgil; Edward T H Yeh
Journal:  J Am Coll Cardiol       Date:  2017-11-14       Impact factor: 24.094

2.  Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib.

Authors:  Tracy E Wiczer; Lauren B Levine; Jessica Brumbaugh; Jessica Coggins; Qiuhong Zhao; Amy S Ruppert; Kerry Rogers; Anli McCoy; Luay Mousa; Avirup Guha; Nyla A Heerema; Kami Maddocks; Beth Christian; Leslie A Andritsos; Samantha Jaglowski; Steven Devine; Robert Baiocchi; Jennifer Woyach; Jeffrey Jones; Michael Grever; Kristie A Blum; John C Byrd; Farrukh T Awan
Journal:  Blood Adv       Date:  2017-09-08

3.  Ibrutinib Displays Atrial-Specific Toxicity in Human Stem Cell-Derived Cardiomyocytes.

Authors:  Sanam Shafaattalab; Eric Lin; Effimia Christidi; Haojun Huang; Yulia Nartiss; Analucia Garcia; Jeehon Lee; Stephanie Protze; Gordon Keller; Liam Brunham; Glen F Tibbits; Zachary Laksman
Journal:  Stem Cell Reports       Date:  2019-04-25       Impact factor: 7.765

4.  Profound Sinoatrial Arrest Associated with Ibrutinib.

Authors:  Kanupriya Mathur; Aditya Saini; Kenneth A Ellenbogen; Richard K Shepard
Journal:  Case Rep Oncol Med       Date:  2017-12-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.